Home › Research › Tau biomarkers
Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: insights from a clinical case series
Ana Silvia Sobreira Lima Verde, Alessandra Braga Cruz Guedes de Morais, Amanda Vale Catunda, João Igor Dantas Landim, Ian Silva Ribeiro, Bruno Diógenes Iepsen, Norberto Anízio Ferreira Frota. Arquivos de neuro-psiquiatria, 2025-11-28
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Cerebral amyloid angiopathy (CAA) is a small vessel disease characterized by the deposition of amyloid-beta in small cerebral vessels, which can lead to intracerebral hemorrhages and cognitive impairment. Rare variants, such as cerebral amyloid angiopathy-related inflammation (CAA-ri) and iatrogenic CAA (ICAA), may mimic other neurological conditions and challenge diagnosis in clinical practice. We present three cases that illustrate distinct CAA syndromes, along with CSF biomarker analysis. One patient experienced recurrent hemorrhagic strokes with a history of dural graft, raising concerns about amyloid transmission. Two patients presented with rapidly progressive dementia that fulfilled CAA-ri criteria. All cases exhibited decreased levels of CSF Aβ40 and Aβ42, with one showing elevated p-tau, suggesting comorbid Alzheimer's pathology. Cerebrospinal fluid biomarkers complement neuroimaging in the diagnosis of CAA, aiding in differentiation from other dementias. Early recognition and diagnosis of CAA-ri variants is crucial, because immunotherapy may improve outcomes. Further research is necessary to establish biomarker thresholds and their clinical applicability.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Verde, A. S. S. L., de Morais, A. B. C. G., Catunda, A. V., Landim, J. I. D., Ribeiro, I. S., Iepsen, B. D., et al. (2025). Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: insights from a clinical case series. Arquivos de neuro-psiquiatria. https://doi.org/10.1055/s-0045-1812887
Vancouver
Verde ASSL, de Morais ABCG, Catunda AV, Landim JID, Ribeiro IS, Iepsen BD, et al. Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: insights from a clinical case series. Arquivos de neuro-psiquiatria. 2025. doi:10.1055/s-0045-1812887. PMID: 41314634.
BibTeX
@article{verde2025-41314634,
author = {Verde, Ana Silvia Sobreira Lima and de Morais, Alessandra Braga Cruz Guedes and Catunda, Amanda Vale and Landim, João Igor Dantas and Ribeiro, Ian Silva and Iepsen, Bruno Diógenes and Frota, Norberto Anízio Ferreira},
title = {{Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: insights from a clinical case series}},
journal = {Arquivos de neuro-psiquiatria},
year = {2025},
doi = {10.1055/s-0045-1812887},
pmid = {41314634},
url = {https://doi.org/10.1055/s-0045-1812887}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Two patients presented with rapidly progressive dementia that fulfilled CAA-ri criteria.
- All cases exhibited decreased levels of CSF Aβ40 and Aβ42, with one showing elevated p-tau, suggesting comorbid Alzheimer's pathology.
- Cerebrospinal fluid biomarkers complement neuroimaging in the diagnosis of CAA, aiding in differentiation from other dementias.
- Early recognition and diagnosis of CAA-ri variants is crucial, because immunotherapy may improve outcomes.
- Further research is necessary to establish biomarker thresholds and their clinical applicability.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 27 of the 56 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Arquivos de neuro-psiquiatria) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41314634) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 27 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 27 of the 56 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “amyloid-angiopathy”
228 studies in the library carry the topic tag “amyloid-angiopathy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 228 tagged studies.